MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...
What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease, but a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...
The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.
“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...
Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone lymphoma, a slow ...
(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results